Skip to content
value.today

Variant Bio, Inc.

🇺🇸 New York, New York, USABiotechnologyFounded 2018

Formerly Syngular, Inc.

Total raised
$128 M
3 rounds on record
Latest round
$105 M
Oct 2021
First round on record
Sep 2019
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Variant Bio, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2021$105 MNo. 3$50 to $250 million

Variant Bio, Inc.: Raise no. 3, Oct 2021

Investors in this round

12 investors had bought by the notice of Nov 17, 2021: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$105 M of $105 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Farnum · Executive Officer, Director
  • Stephane Castel · Executive Officer, Director
  • Bob More · Director
  • Elena Viboch · Director
  • Josh Wolfe · Director
  • Julie Sunderland · Director
  • Stuart Nagae · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Andrew Farnum, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Nov 17, 2021. Read the notice at the SEC.

equitySEC
Jul 2020$6 MNo. 2$2 to $10 million

Variant Bio, Inc.: Raise no. 2, Jul 2020

Investors in this round

6 investors had bought by the notice of Aug 5, 2020: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $7 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Farnum · Executive Officer, Director
  • Kaja Wasik · Executive Officer, Director
  • Bob More · Director
  • Josh Wolfe · Director
  • Julie Sunderland · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Andrew Farnum, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 5, 2020. Read the notice at the SEC.

equitySEC
Sep 2019$17 MNo. 1$10 to $50 million

Variant Bio, Inc.: Raise no. 1, Sep 2019

Investors in this round

2 investors had bought by the notice of Oct 10, 2019: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$17 M of $32 M offered; $15 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Akhila Kosaraju · Executive Officer, Director
  • Josh Wolfe · Executive Officer, Director
  • Adam Goulburn · Director
  • Kaja Wasik · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Akhila Kosaraju, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 10, 2019. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Variant Bio, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2021).

    SEC Form D · Nov 2021

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Nov 2021

That is all the official record says: Variant Bio, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Variant Bio, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 12 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Variant Bio, Inc.
NameRoleNamed in
Andrew FarnumExecutive officerNov 2021
Stephane CastelExecutive officerNov 2021
Kaja WasikExecutive officerAug 2020
Akhila KosarajuExecutive officerOct 2019
Josh WolfeExecutive officerOct 2019
Andrew FarnumDirectorNov 2021
Bob MoreDirectorNov 2021
Elena VibochDirectorNov 2021
Josh WolfeDirectorNov 2021
Julie SunderlandDirectorNov 2021
Stephane CastelDirectorNov 2021
Stuart NagaeDirectorNov 2021
Kaja WasikDirectorAug 2020
Adam GoulburnDirectorOct 2019
Akhila KosarajuDirectorOct 2019